Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark

被引：0
|
作者：
Nielsen, Katrine Finderup [1 ,4 ]
Nielsen, Lise Birk [1 ]
Dalby, Tine [1 ]
Lomholt, Frederikke Kristensen [1 ]
Slotved, Hans-Christian [1 ]
Fuursted, Kurt [1 ]
Harboe, Zitta Barrella [1 ,2 ,3 ]
Jorgensen, Charlotte Svaerke [1 ]
Valentiner-Branth, Palle [1 ]
机构：
[1] Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen S, Denmark
[2] Copenhagen Univ Hosp, Copenhagen, Denmark
[3] Univ Copenhagen, Copenhagen, Denmark
[4] Statens Serum Inst, Artillerivej 5, DK-2300 Copenhagen, Denmark
来源：
EMERGING INFECTIOUS DISEASES | 2024年 / 30卷 / 06期
关键词：
AGED; 65; ENGLAND; PNEUMONIA; PEOPLE; ADULTS; IMPACT; OLDER;
D O I：
10.3201/eid3006.230975
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >= 65 years of age as part of a vaccination program in Denmark during Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.
引用
收藏
页码：1164 / 1172
页数：9
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
    Choi, Min-Joo
    Kang, Shin-On
    Oh, Jin-Jeong
    Park, Seong-Beom
    Kim, Min-Ja
    Cheong, Hee-Jin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1914 - 1922
  • [42] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
    Gouveia, Miguel
    Jesus, Goncalo
    Ines, Monica
    Costa, Joao
    Borges, Margarida
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
  • [43] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
  • [44] Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease
    Meng, Chun
    Lin, Haiying
    Huang, Jinzhong
    Wang, Hang
    Cai, Qianyin
    Fang, Liang
    Guo, Yanghao
    MICROBIAL PATHOGENESIS, 2009, 47 (03) : 151 - 156
  • [45] THE COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN TAIWAN
    Wu, D. B. C.
    Chang, C. J.
    Chien, L.
    Fang, H. C. H.
    Roberts, C. S.
    VALUE IN HEALTH, 2012, 15 (07) : A602 - A602
  • [46] Protective Effects of 23-Valent Pneumococcal Polysaccharide Vaccination Against Mortality: The VENUS Study
    Murata, Fumiko
    Maeda, Megumi
    Fukuda, Haruhisa
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (09):
  • [47] Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center
    Toshihiro Masuda
    Eiji Nakatani
    Toshihiro Shirai
    Taisuke Akamatsu
    Kanami Tamura
    Shingo Takahashi
    Yuko Tanaka
    Hirofumi Watanabe
    Yoshinari Endo
    Takahito Suzuki
    Mika Saigusa
    Akito Yamamoto
    Satoru Morita
    Yoko Sato
    Kazuhiro Asada
    BMC Pulmonary Medicine, 21
  • [48] Impact of the Start of Follow-Up on Estimates of Incidence Rates of Prespecified Outcomes Following Administration of 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23)
    Titievsky, Lina
    Esposito, Daina B.
    Hawes, Jennifer C. L.
    Holick, Crystal N.
    Maroko, Robert
    Hollingsworth, Rosalind C.
    Lanes, Stephan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 543 - 544
  • [49] Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults
    Hsiao, Amber
    Lewis, Ned
    Hansen, John
    Timbol, Julius
    Suaya, Jose A.
    Alexander-Parrish, Ronika
    Grant, Lindsay R.
    Gessner, Bradford D.
    Klein, Nicola P.
    VACCINE, 2025, 44
  • [50] Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study
    Kabir, Alamgir
    Randall, Deborah
    Newall, Anthony T.
    Moore, Hannah C.
    Jayasinghe, Sanjay
    Fathima, Parveen
    Liu, Bette
    Mcintyre, Peter
    Gidding, Heather F.
    VACCINE, 2023, 41 (37) : 5454 - 5460
12345